A vir­tu­al biotech in­cu­ba­tor is launch­ing with the help of Evotec and Sam­sara, look­ing for a few good sci­en­tists in need of seed cash for spin­outs

By any mea­sure, mon­ey has been pour­ing in­to the bio­phar­ma R&D field for more than 5 years now, with every stage of de­vel­op­ment crowd­ed with in­vestors look­ing for the next big thing in ther­a­peu­tics.

Val­ue in­flec­tion points are the guid­ing star of that multi­bil­lion-dol­lar busi­ness.

But a busy Sam­sara Bio­Cap­i­tal, the fam­i­ly fund KCK and the big Eu­ro­pean CRO Evotec are back­ing the play of a pair of in­vestors who have staked out a field where there doesn’t seem to be quite so much den­si­ty.

Tom No­vak and Michelle Kim-Dane­ly are launch­ing a vir­tu­al in­cu­ba­tor called Au­to­bahn Labs, which is at the be­gin­ning stages of ink­ing deals with aca­d­e­m­ic labs to seed spin­out com­pa­nies for their dis­cov­er­ies. Sam­sara and KCK are pro­vid­ing up to $5 mil­lion per op­er­a­tion, with Evotec on board to lend its ex­ten­sive con­tract plat­form sup­port to the fledg­lings that sign on. And the sci­en­tists can al­so tap Au­to­bahn’s ad­vi­so­ry group as they steer their lit­tle com­pa­nies through pre­clin­i­cal de­vel­op­ment.

Tom No­vak

“Our plan,” No­vak tells me, “is to en­ter in­to part­ner­ships with ma­jor uni­ver­si­ties and find pro­grams that are at very ear­ly stage, 3 to 4 years ahead of the clin­ic.”

And the rare few that make it to launch can look to one of their in­vestors to take the lead on an A round.

To get start­ed, Au­to­bahn has signed up UCLA on kind of a mas­ter con­tract that lays out the terms cov­er­ing IP and eq­ui­ty and so on — and no, they aren’t de­tail­ing the par­tic­u­lars of the con­tract to me.

For sci­en­tists with­out se­lect VCs on speed di­al, that might look quite ap­peal­ing. And now No­vak and Kim-Dane­ly are look­ing to repli­cate the UCLA deal, pri­mar­i­ly along the West Coast but al­so back east as well as Eu­rope.

Michelle Kim-Dane­ly

Both of the prin­ci­pals at Au­to­bahn are re­al­is­tic about the like­li­hood of fail­ure. They es­ti­mate that 85% to 90% of their seed plays won’t make it to the clin­ic and that next lev­el of de­vel­op­ment. But get­ting 1 out of 10 small in­vest­ments to pay off could work out well. No­vak says they have enough mon­ey for 8 on­go­ing projects at a time.

“It’s im­por­tant to have dif­fer­ent mod­els, dif­fer­ent sweet spots,” says Kim-Dane­ly. “For uni­ver­si­ties it’s an­oth­er ar­row in their quiv­ers.”

As for dis­ease ar­eas and tech, the two say they are com­plete­ly ag­nos­tic.

Pi­o­neer­ing Click Chem­istry in Hu­mans

Reimagining cancer treatments

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, which is nearly one in six deaths. Recently, we have seen incredible advances in novel cancer therapies such as immune checkpoint inhibitors, cell therapies, and antibody-drug conjugates that have revamped cancer care and improved survival rates for patients.

Despite this significant progress in therapeutic targeting, why are we still seeing such a high mortality rate? The reason is that promising therapies are often limited by their therapeutic index, which is a measure of the effective dose of a drug, relative to its safety. If we could broaden the therapeutic indices of currently available medicines, it would revolutionize cancer treatments. We are still on the quest to find the ultimate cancer medicine – highly effective in several cancer types, safe, and precisely targeted to the tumor site.

Joshua Cohen (L) and Justin Klee, Amylyx co-CEOs

BREAK­ING: Af­ter long and wind­ing road, FDA ap­proves Amy­lyx's ALS drug in vic­to­ry for pa­tients and ad­vo­ca­cy groups

For just the third time in its 116-year history, the FDA has approved a new treatment for Lou Gehrig’s disease, or ALS.

US regulators gave the thumbs-up to the drug, known as Relyvrio, in a massive win for patients and their families. The approval, given to Boston-area biotech Amylyx Pharmaceuticals, comes after two years of long and contentious debates over the drug’s effectiveness between advocacy groups and FDA scientists, following the readout of a mid-stage clinical trial in September 2020.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,200+ biopharma pros reading Endpoints daily — and it's free.

Ivan Cheung, Eisai US chairman and CEO

Bio­gen, Ei­sai re­fresh amy­loid hy­poth­e­sis with PhI­II show­ing Alzheimer's med slows cog­ni­tive de­cline

In the first look at Phase III data for lecanemab, Eisai and Biogen’s follow-up Alzheimer’s drug to the embattled Aduhelm launch, results show the drug passed with flying colors on a test looking at memory, problem solving and other dementia metrics.

One of the most-watched Alzheimer’s therapies in the clinic, lecanemab met the study’s primary goal on the CDR-SB — Clinical Dementia Rating-Sum of Boxes — giving the biotech the confidence to ask for full approval in the US, EU and Japan by next March 31. The experimental drug reduced clinical decline on the scale by 27% compared to placebo at 18 months, the companies said Tuesday night Eastern time and Wednesday morning in Japan.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,200+ biopharma pros reading Endpoints daily — and it's free.

Nooman Haque, head of life sciences and healthcare at Silicon Valley Bank, and John Carroll

I’m head­ed to Lon­don soon for #EU­BIO22. Care to join me?

It was great getting back to a live ESMO conference/webinar in Paris followed by a live pop-up event for the Endpoints 11 in Boston. We’re staying on the road in October with our return for a live/streaming EUBIO22 in London.

Silicon Valley Bank’s Nooman Haque and I are once again jumping back into the thick of it with a slate of virtual and live events on October 12. I’ll get the ball rolling with a virtual fireside chat with Novo Nordisk R&D chief Marcus Schindler, covering their pipeline plans and BD work.

Some­one old, some­one new: Mod­er­na pro­motes CTO, raids No­var­tis for re­place­ment amid pipeline push

Moderna CEO Stéphane Bancel made clear on the last quarterly call that “now is not the time to slow down.” On Thursday, he made a bit more room in the cockpit.

The company unveiled a new executive role on Thursday, promoting former chief technical operations and quality officer Juan Andres to president of strategic partnerships and enterprise expansion, and poaching a former Novartis exec to take his place.

Gilead names 'k­ing­pin­s' in coun­ter­feit HIV med law­suit

Gilead is mounting its counterfeit drug lawsuit, naming two “kingpins” and a complex network of conspirators who allegedly sold imitation bottles of its HIV meds, some of which ended up in US pharmacies.

The pharma giant on Wednesday provided an update on what it called a “large-scale, sophisticated counterfeiting conspiracy,” accusing two new defendants of “leading and orchestrating” a scheme to sell hundreds of millions of dollars in illegitimate drugs posing as meds such as Biktarvy and Descovy.

Vlad Coric, Biohaven CEO (Photo Credit: Andrew Venditti)

As Amy­lyx de­ci­sion waits in the wings, Bio­haven’s ALS drug sinks (again) in plat­form tri­al

The FDA’s decision on Amylyx’s ALS drug is set to come out sometime Thursday. In a space with few drugs, any approval would be a major landmark.

But elsewhere in the ALS field, things are a bit more tepid.

Thursday morning, Biohaven announced that its drug verdiperstat failed its arm of an ALS platform trial led by Massachusetts General Hospital. According to a press release, the drug did not meet its primary endpoint — improvement on an ALS functional status test — or any key secondary endpoints at 24 weeks. The trial had enrolled 167 patients, giving them either verdiperstat or placebo twice a day.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,200+ biopharma pros reading Endpoints daily — and it's free.

Tar­sus looks to raise aware­ness of eye­lid mite dis­ease in cam­paign aimed at eye­care spe­cial­ists

Eyelid mite disease may be “gross” but it’s also fairly common, affecting about 25 million people in the US.

Called demodex blepharitis, it’s a well-known condition among eyecare professionals, but they often don’t always realize how common it is. Tarsus Pharmaceuticals wants to change that with a new awareness campaign called “Look at the Lids.”

The campaign and website debut Thursday — just three weeks after Tarsus filed for FDA approval for a drug that treats the disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,200+ biopharma pros reading Endpoints daily — and it's free.

Marcelo Bigal, Ventus Therapeutics CEO

No­vo Nordisk joins No­var­tis, Roche in NL­RP3 are­na, bet­ting $70M cash on NASH, car­diometa­bol­ic us­es

As a drug target, the NLRP3 inflammasome has drawn serious interest from Big Pharma, inspiring a series of M&A deals from Novartis and Roche on top of venture investments by others. Now Novo Nordisk is jumping on the bandwagon — and the Danish pharma giant is taking the target where it knows best.

Novo Nordisk is getting its NLRP3 inhibitors from Ventus Therapeutics, a Versant-backed startup that set out to make some of the best NLRP3 drugs out there by incorporating new insights into the structure of the target complex.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,200+ biopharma pros reading Endpoints daily — and it's free.